We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The Food and Drug Administration (FDA) has entered into a collaborative agreement with the World Health Organization (WHO) in an effort to support the development of a global surveillance and monitoring system for combating counterfeit medicines and breaches in the supply chain
